Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Protagonist Therapeutics Q2 EPS $(0.69) Down From $(0.59) YoY

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.69) per share. This is a 16.95 percent decrease over losses of $(0.59) per share from the same period last year.

byBill Haddad

August 4, 2021

1 minute read

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.69) per share. This is a 16.95 percent decrease over losses of $(0.59) per share from the same period last year.

News

Watching Penn National Gaming; Dave Portnoy Tweets ‘Emergency Press Conference – Julia Black and Business Insider Are Preparing to Drop Another Make Believe Hit Piece on Me Today’

By Benzinga Newsdesk

Today, 2:38 AM

https://twitter.com/stoolpresidente/status/1484194008444375042

PENN

CannTrust Changes Name To Phoena, Here Is What You Need To Know

By Vuk Zdinjak

Today, 2:38 AM

CannTrust Equity Inc. announced its new corporate name, Phoena Holdings Inc.

CNTTQ

Here’s How Much $100 Invested In Cenovus Energy 5 Years Ago Would Be Worth Today

By Benzinga Insights

Today, 2:38 AM

Cenovus Energy (NYSE:CVE) has outperformed the market over the past 5 years by 8.47% on an annualized basis producing an average annual return of 17.65%. Currently, Cenovus Energy has a market capitalization of $33.11 billion.

CVE